Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Investors | Eli Lilly and CompanyEli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBCEli Lilly stock surges on Q2 earnings beat, revenue outlook Yahoo FinanceEli Lilly Lifts 2024 Sales Outlook as Zepbound Demand Drives Quarter BloombergEli Lilly Stock Rises Sharply on Guidance Hike and Zepbound Sales Beat Barron’s